2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
13
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
rozanolixizumab
11
efgartigimod alfa
10
zilucoplan
8
Prednisone
8
Cyclophosphamide
8
ravulizumab
7
Rituximab
7
Pyridostigmine Bromide
7
telitacicept
6
fludarabine
6
Tacrolimus
6
Mycophenolic Acid
6
eculizumab
5
Immunoglobulins, Intravenous
5
Hizentra
4
Azathioprine
4
Steroids
3
HBM9161
3
Data Collection
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Thymectomy
2
Prednisolone
2
Methylprednisolone
2
Methotrexate
2
Exercise
2
Diagnostic Self Evaluation
2
Blood Specimen Collection
2
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Sodium Chloride
×
Clear all
NCT02950155
2024-10-26
Rinomax
Karolinska Institutet
Phase 3
Completed
47 enrolled
24 charts